PT  - JOURNAL ARTICLE
AU  - Alsentzer, Emily
AU  - Li, Michelle M.
AU  - Kobren, Shilpa N.
AU - Undiagnosed Diseases Network
AU  - Kohane, Isaac S.
AU  - Zitnik, Marinka
TI  - Deep learning for diagnosing patients with rare genetic diseases
AID  - 10.1101/2022.12.07.22283238
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.07.22283238
4099  - http://medrxiv.org/content/early/2022/12/13/2022.12.07.22283238.short
4100  - http://medrxiv.org/content/early/2022/12/13/2022.12.07.22283238.full
AB  - There are more than 7,000 rare diseases, some of which affect 3,500 or fewer patients in the US. Due to clinicians’ limited experience with such diseases and the considerable heterogeneity of their clinical presentations, many patients with rare genetic diseases remain undiagnosed. While artificial intelligence has demonstrated success in assisting diagnosis, its success is usually contingent on the availability of large labeled datasets. Here, we present shepherd, a deep learning approach for multi-faceted rare disease diagnosis. shepherd is guided by existing knowledge of diseases, phenotypes, and genes to learn novel connections between a patient’s clinico-genetic information and phenotype and gene relationships. We train shepherd exclusively on simulated patients and evaluate on a cohort of 465 patients representing 299 diseases (79% of genes and 83% of diseases are represented in only a single patient) in the Undiagnosed Diseases Network. shepherd excels at several diagnostic facets: performing causal gene discovery (causal genes are predicted at rank = 3.52 on average), retrieving “patients-like-me” with the same gene or disease, and providing interpretable characterizations of novel disease presentations. shepherd demonstrates the potential of artificial intelligence to accelerate the diagnosis of rare disease patients and has implications for the use of deep learning on medical datasets with very few labels.Competing Interest StatementThe authors have declared no competing interest.Funding StatementE.A. is supported by a Microsoft Research PhD Fellowship. M.L. is supported by T32HG002295 from the National Human Genome Research Institute and a National Science Foundation Graduate Research Fellowship. M.Z. gratefully acknowledges the support by NSF under Nos. IIS-2030459 and IIS-2033384, US Air Force Contract No. FA8702-15-D-0001, and awards from Harvard Data Science Initiative, Amazon Research, Bayer Early Excellence in Science, AstraZeneca Research, and Roche Alliance with Distinguished Scientists. UDN research reported in this manuscript was supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under the following award numbers: U01HG007709, U01HG010219, U01HG010230, U01HG010217, U01HG010233, U01HG010215, U01HG007672, U01HG007690, U01HG007708, U01HG007703, U01HG007674, U01HG007530, U01HG007942, U01HG007943, U01TR001395, U01TR002471, U54NS108251, and U54NS093793. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health and other funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Undiagnosed Diseases Network study is approved by the National Institutes of Health institutional review board (IRB), which serves as the central IRB for the study (Protocol 15HG0130).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the paper, including the rare disease knowledge graph, simulated and MyGene2 cohorts, and the final and intermediate results of the analyses are shared with research community at https://zitniklab.hms.harvard.edu/projects/SHEPHERD. While the Undiagnosed Diseases Network (UDN) dataset cannot be released in its entirety due to privacy concerns, anonymized UDN data has been deposited in dbGaP (accession phs001232) and PhenomeCentral. Phenotypes and causal variants and genes related to UDN diagnoses are also shared publicly in ClinVar at https://www.ncbi. nlm.nih.gov/clinvar/submitters/505999. The UDN study is approved by the NIH IRB Protocol 15HG0130. All patients accepted to the UDN provide written informed consent to share their data across the UDN.https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/TZTPFL https://github.com/mims-harvard/SHEPHERD https://huggingface.co/spaces/emilyalsentzer/SHEPHERD https://zitniklab.hms.harvard.edu/projects/SHEPHERD